HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness.

Abstract
Hypoxic microenvironment is common in solid tumors, particularly in pancreatic ductal adenocarcinoma (PDAC). The Warburg effect is known to facilitate cancer aggressiveness and has long been linked to hypoxia, yet the underlying mechanism remains largely unknown. In this study, we identify that lysyl oxidase-like 2 (LOXL2) is a hypoxia-responsive gene and is essential for the Warburg effect in PDAC. LOXL2 stabilizes hypoxia-inducible factor 1α (HIF1α) from prolyl hydroxylase (PHD)-dependent hydroxylation via hydrogen peroxide generation, thereby facilitating the transcription of multiple glycolytic genes. Therefore, a positive feedback loop exists between LOXL2 and HIF1α that facilitates glycolytic metabolism under hypoxia. Moreover, LOXL2 couples the Warburg effect to tumor growth and metastasis in PDAC. Hijacking glycolysis largely compromises LOXL2-induced oncogenic activities. Collectively, our results identify a hitherto unknown hypoxia-LOXL2-HIF1α axis in regulating the Warburg effect and provide an intriguing drug target for PDAC therapy.
AuthorsRongkun Li, Hengchao Li, Lili Zhu, Xiaoxin Zhang, Dejun Liu, Qing Li, Bo Ni, Lipeng Hu, Zhigang Zhang, Yanli Zhang, Xu Wang, Shu-Heng Jiang
JournalCell death & disease (Cell Death Dis) Vol. 12 Issue 12 Pg. 1106 (11 26 2021) ISSN: 2041-4889 [Electronic] England
PMID34836938 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Amino Acid Oxidoreductases
  • LOXL2 protein, human
Topics
  • Adenocarcinoma (genetics, pathology)
  • Amino Acid Oxidoreductases (metabolism)
  • Carcinoma, Pancreatic Ductal (genetics, pathology)
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit (metabolism)
  • Tumor Microenvironment
  • Warburg Effect, Oncologic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: